Replies to post #171837 on Biotech Values

[DewDiligence]

CANF—All in all, even if used pre and post anti-TNFs, I don't expect [CF101] to have a substantial market uptake in RA (I see a better future for it in psoriasis).

Can you elaborate on your reasons? Psoriasis has become almost as competitive a marketplace as RA.